Emerging Multiple Sclerosis Therapies

Slides:

Advertisements

Similar presentations

Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer

Advertisements

Immune Depletion, Immune Modulation, and Immunosuppression in MS: A Review.

Highlights From the 2015 European Multiple Sclerosis Meeting

Highlights From the 2017 Annual European MS Meeting

Why New Treatments for Schizophrenia Should Be on Your Radar

Perspectives on Key MS Data From the Annual European MS Meeting

MS Highlights From the 2017 Annual Neurology Meeting

T-Cell Exhaustion: Can We Overcome It in Cancer?

Current and Emerging Treatments for IBD

Immune Reconstitution in MS:

Migraine Prevention Therapy: Avoiding Overuse of Medications

Perspectives on Key MS Data From the Annual Neurology Meeting

What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?

Prolonging Progression-Free Survival in Follicular Lymphoma

Unmet Needs in Schizophrenia

T-Cell Directed Therapy in MS

Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.

New Data in nAMD: What Does the Future Hold?

The Vicious Cycle of Chronic Migraine How Can the Physician Help?

Challenges in Managing Progressive Multiple Sclerosis

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Updates in Migraine From a 2018 American Headache Meeting

Addressing Disease Burden in Asthma

Novel Therapies for the Treatment of MS

Diagnostic and Management Challenges in Patients With Chronic Migraine

Postpartum Depression

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Next-Gen Psoriasis Therapies:

Evaluating Next-Generation BTK Inhibitors

Case Studies in Unresectable Hepatocellular Carcinoma

The JAK-STAT Pathway and Graft-vs-Host Disease

CGRP Antibodies in Migraine

Radical New Concepts in Lipid Management

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.

New Data on Emerging Treatments for Psoriasis

Breaking New Ground With Migraine Prevention Therapies

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Developments in the Wet AMD Treatment Landscape

Getting to Grips With the Science of CGRP and Migraine

Advances in Immunotherapy for Peanut Allergy

Expert Perspectives on New Data in Multiple Sclerosis From the 2018 European MS Meeting.

Clinical Pearls on Hot Topics in MS

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

The Rising Cost of Healthcare and Potential Impact of Biosimilars

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

FLT3 Inhibitors in AML.

Application of Biologics in IBD:

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Why Opioid Withdrawal Syndrome Should Be on Your Radar

Challenges and Opportunities

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a.

The ABCs of Pharmacogenomics in Clinical Practice

Program Goals Overview Natalizumab Natalizumab: Recent Label Changes.

Secondary Progressive Multiple Sclerosis: What Do We Know and Where Are We Heading?

New Paradigms in M0 CRPC.

Peanut Allergy Immunotherapy

Novel Therapeutics in MS

Peanut Allergy Immunotherapy

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Spotlight on Monoclonal Antibodies in Multiple Myeloma

Mitigating Infection Risk With DMT in MS

The ABCs of Therapeutic Strategies in Pregnancy and Multiple Sclerosis

Using Biomarkers in MS: Initiating With the Right Therapy in Clinical Practice.

Updates in Progressive MS

The Changing Face of Multiple Sclerosis: What Are the Experts Looking Forward To?

Selective Immunomodulation in MS

Presentation transcript:

Emerging Multiple Sclerosis Therapies

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Emerging DMTs and Unmet Needs in MS

Overview of Selected DMTs in Development

Cladribine

Cladribine vs Placebo in RRMS CLARITY

Cladribine vs Placebo in RRMS Post-Hoc Analyses of CLARITY

Cladribine vs Placebo in RRMS CLARITY Extension

S1P Receptor Modulators

Siponimod vs Placebo in SPMS EXPAND

Ozanimod vs IFN β-1a IM in RRMS SUNBEAM

Ozanimod vs IFN β-1a IM in RRMS RADIANCE Part B

Ponesimod vs Teriflunomide in RRMS OPTIMUM

Ponesimod + DMF vs DMF in RRMS POINT

ALKS 8700

ALKS 8700 vs DMF in RRMS EVOLVE-MS-1 and EVOLVE-MS-2

Monoclonal Antibodies Targeting CD20

Ofatumumab vs Placebo in RRMS MIRROR Phase 2 Study

Ofatumumab vs Teriflunomide in RRMS ASCLEPIOS I and ASCLEPIOS II

Ublituximab in RRMS Phase 2 Study

Ublituximab vs Teriflunomide in RRMS ULTIMATE I and ULTIMATE II

Opicinumab Anti-LINGO-1

Opicinumab vs Placebo in Optic Neuritis RENEW Phase 2 Study

Opicinumab + IFN β-1a IM vs IFN β-1a IM in RRMS or SPMS: SYNERGY Phase 2 Study

Temelimab (GNbAC1) Anti-MSRV-Env

Temelimab vs Placebo in RRMS: CHANGE-MS Phase 2 Study

Ibudilast

Ibudilast vs Placebo in SPMS and PPMS SPRINT-MS

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)